Exact Mass: 495.3874268
Exact Mass Matches: 495.3874268
Found 141 metabolites which its exact mass value is equals to given mass value 495.3874268,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Orlistat
Orlistat is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. Orlistat works by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested. A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AB - Peripherally acting antiobesity products C471 - Enzyme Inhibitor > C29715 - Gastrointestinal Lipase Inhibitor D057847 - Lipid Regulating Agents D019440 - Anti-Obesity Agents D004791 - Enzyme Inhibitors Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity[1].?Anti-atherosclerotic?effect[2].
(13Z,16Z)-3-Hydroxydocosa-13,16-dienoylcarnitine
(13Z,16Z)-3-Hydroxydocosa-13,16-dienoylcarnitine is an acylcarnitine. More specifically, it is an (13Z,16Z)-3-hydroxydocosa-13,16-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (13Z,16Z)-3-Hydroxydocosa-13,16-dienoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (13Z,16Z)-3-Hydroxydocosa-13,16-dienoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(14Z)-Tricos-14-enoylcarnitine
C30H57NO4 (495.42873620000006)
(14Z)-Tricos-14-enoylcarnitine is an acylcarnitine. More specifically, it is an (14Z)-tricos-14-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (14Z)-Tricos-14-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (14Z)-Tricos-14-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(18Z)-Tricos-18-enoylcarnitine
C30H57NO4 (495.42873620000006)
(18Z)-Tricos-18-enoylcarnitine is an acylcarnitine. More specifically, it is an (18Z)-tricos-18-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (18Z)-Tricos-18-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (18Z)-Tricos-18-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(17Z)-Tricos-17-enoylcarnitine
C30H57NO4 (495.42873620000006)
(17Z)-Tricos-17-enoylcarnitine is an acylcarnitine. More specifically, it is an (17Z)-tricos-17-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (17Z)-Tricos-17-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (17Z)-Tricos-17-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(9Z)-Tricos-9-enoylcarnitine
C30H57NO4 (495.42873620000006)
(9Z)-Tricos-9-enoylcarnitine is an acylcarnitine. More specifically, it is an (9Z)-tricos-9-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z)-Tricos-9-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (9Z)-Tricos-9-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Nervonoyl Glutamic acid
N-nervonoyl glutamic acid, also known as N-nervonoyl glutamate belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Nervonic acid amide of Glutamic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Nervonoyl Glutamic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Nervonoyl Glutamic acid is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N(4)-Octadecyl-1-arabinofuranosylcytosine
C27H49N3O5 (495.36720240000005)
1-O-hexadecyl-2-C-methyl-3-phosphatidylcholine
C25H54NO6P (495.36885540000003)
Acquisition and generation of the data is financially supported by the Max-Planck-Society
cyclo (-Gly-L-Orn-L-Ile-3-amino-10-methyldodecanoyl-)|rhodopeptin C2
C26H49N5O4 (495.37843540000006)
lycoperine A
An alkaloid that consists of piperidine substituted by [1-acetyl-7-methyl-1,2,3,4,6,7,8,8a-octahydroquinolin-5-yl]methyl moieties at positions 2 and 6 respectively. Isolated from Lycopodium hamiltonii, it exhibits acetylcholinesterase inhibitory activity.
cyclo (-GlyL-Orn-L-Val-3-amino-12-methyltridecanoyl-)|rhodopeptin C3
C26H49N5O4 (495.37843540000006)
1-O-Hexadecyl-2-O-methyl-rac-glycero-3-phosphocholine
C25H54NO6P (495.36885540000003)
Orlistat
A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug. A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AB - Peripherally acting antiobesity products C471 - Enzyme Inhibitor > C29715 - Gastrointestinal Lipase Inhibitor D057847 - Lipid Regulating Agents D019440 - Anti-Obesity Agents D004791 - Enzyme Inhibitors CONFIDENCE standard compound; INTERNAL_ID 2362 CONFIDENCE standard compound; INTERNAL_ID 8541 Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity[1].?Anti-atherosclerotic?effect[2].
PC(O-1:0/O-16:0)[U]
C25H54NO6P (495.36885540000003)
PC(O-16:0/O-1:0)
C25H54NO6P (495.36885540000003)
PC(O-16:0/O-1:0)[S]
C25H54NO6P (495.36885540000003)
ET 16OME
C25H54NO6P (495.36885540000003)
PC(O-17:0/0:0)
C25H54NO6P (495.36885540000003)
2-O-methyl PAF C-16
C25H54NO6P (495.36885540000003)
Dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride
N-Formyl-L-leucine (3S,4R,6S)-3-Hexyl-3,4,5,6-tetrahydro-2-oxo-6-undecyl-2H-pyran-4-yl Ester
(3-Hexadecoxy-2-hydroxy-2-methylpropyl) 2-(trimethylazaniumyl)ethyl phosphate
C25H54NO6P (495.36885540000003)
N-(2-hydroxydodecanoyl)-sphinga-4,8-dienine
C30H57NO4 (495.42873620000006)
(16Z,19Z,22Z,25Z,28Z,31Z)-tetratriacontahexaenoate
C34H55O2- (495.42018299999995)
A polyunsaturated fatty acid anion that is the conjugate base of (16Z,19Z,22Z,25Z,28Z,31Z)-tetratriacontahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
1-o-Heptadecyl-2-hydroxy-sn-glycero-3-phosphocholine
C25H54NO6P (495.36885540000003)
2-Aminoethyl (2-hydroxy-3-icosoxypropyl) hydrogen phosphate
C25H54NO6P (495.36885540000003)
(3Z,6Z,9Z,12Z,15Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]octadeca-3,6,9,12,15-pentaenamide
N-[(8E,12E)-1,3,4-trihydroxypentadeca-8,12-dien-2-yl]pentadecanamide
C30H57NO4 (495.42873620000006)
(Z)-N-[(E)-1,3,4-trihydroxyoctadec-8-en-2-yl]dodec-5-enamide
C30H57NO4 (495.42873620000006)
N-[(8E,12E)-1,3,4-trihydroxyheptadeca-8,12-dien-2-yl]tridecanamide
C30H57NO4 (495.42873620000006)
(Z)-N-[(E)-1,3,4-trihydroxytetradec-8-en-2-yl]hexadec-7-enamide
C30H57NO4 (495.42873620000006)
(Z)-N-[(E)-1,3,4-trihydroxypentadec-8-en-2-yl]pentadec-9-enamide
C30H57NO4 (495.42873620000006)
(Z)-N-[(E)-1,3,4-trihydroxyheptadec-8-en-2-yl]tridec-8-enamide
C30H57NO4 (495.42873620000006)
(4Z,7Z)-N-(1,3,4-trihydroxytetradecan-2-yl)hexadeca-4,7-dienamide
C30H57NO4 (495.42873620000006)
N-[(8E,12E)-1,3,4-trihydroxyhexadeca-8,12-dien-2-yl]tetradecanamide
C30H57NO4 (495.42873620000006)
N-[(8E,12E)-1,3,4-trihydroxyoctadeca-8,12-dien-2-yl]dodecanamide
C30H57NO4 (495.42873620000006)
N-[(8E,12E)-1,3,4-trihydroxytetradeca-8,12-dien-2-yl]hexadecanamide
C30H57NO4 (495.42873620000006)
(Z)-N-[(E)-1,3,4-trihydroxyhexadec-8-en-2-yl]tetradec-9-enamide
C30H57NO4 (495.42873620000006)
2-[Hydroxy-[3-hydroxy-2-(nonanoylamino)decoxy]phosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(propanoylamino)hexadecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[(2-Acetamido-3-hydroxyheptadecoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(octanoylamino)undecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-(Hexanoylamino)-3-hydroxytridecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-(Butanoylamino)-3-hydroxypentadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(pentanoylamino)tetradecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-(Heptanoylamino)-3-hydroxydodecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(undecanoylamino)octoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-(Decanoylamino)-3-hydroxynonoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
1-heptadecyl-sn-glycero-3-phosphocholine
C25H54NO6P (495.36885540000003)
1-eicosyl-glycero-3-phosphoethanolamine
C25H54NO6P (495.36885540000003)
tetratriacontahexaenoate
A polyunsaturated fatty acid anion that is the conjugate base of tetratriacontahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
LdMePE(18:0)
C25H54NO6P (495.36885540000003)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
AcCa(23:1)
C30H57NO4 (495.42873620000006)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
6-(3-aminopropyl)-13-(7-methylnonyl)-3-(sec-butyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
(3s,6s,13r)-6-(3-aminopropyl)-3-isopropyl-13-(9-methyldecyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
(3s,6s)-6-(3-aminopropyl)-13-(7-methylnonyl)-3-(sec-butyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
6-(3-aminopropyl)-3-isopropyl-13-(9-methyldecyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
(3s,6s)-6-(3-aminopropyl)-3-isopropyl-13-(9-methyldecyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
(3s,6s,13r)-6-(3-aminopropyl)-13-(7-methylnonyl)-3-(sec-butyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraene-2,5,8,11-tetrol
C26H49N5O4 (495.37843540000006)
(2-{[(2r)-2-hydroxy-3-[(15-methylhexadecyl)oxy]propyl phosphonato]oxy}ethyl)trimethylazanium
C25H54NO6P (495.36885540000003)
(3s,6s,9r)-13-heptyl-5,8,11-trihydroxy-3-isopropyl-6,9-bis(2-methylpropyl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
C27H49N3O5 (495.36720240000005)